(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
27 February 2020 (27.02.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/041466 A1

(51) International Patent Classification:
A61K 31/444 (2006.01) *A61K 31/5377* (2006.01)
A61K 31/505 (2006.01)

(21) International Application Number:
PCT/US2019/047499

(22) International Filing Date:
21 August 2019 (21.08.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/720,782	21 August 2018 (21.08.2018)	US
62/749,052	22 October 2018 (22.10.2018)	US
62/774,752	03 December 2018 (03.12.2018)	US

(71) Applicant: **SIERRA ONCOLOGY, INC.** [US/US]; Michigan Life Science and Innovation Center, 46701 Commerce Center Drive, Plymouth, MI 48170 (US).

(72) Inventors: **KLENCKE, Barbara, Jane**; c/o Sierra Oncology, Inc., Michigan Life Science and Innovation Center, 46701 Commerce Center Drive, Plymouth, MI 48170 (US). **SMITH, Gregg, David**; c/o Sierra Oncology, Inc., Michigan Life Science and Innovation Center, 46701 Commerce Center Drive, Plymouth, MI 48170 (US). **DONAHUE, Rafe, Michael, Joseph**; c/o Sierra Oncology, Inc, Michigan Life Science and Innovation Center, 46701 Commerce Center Drive, Plymouth, MI 48170 (US).

(74) Agent: **FOULDS, Glenn, J.** et al.; Fenwick & West LLP, Silicon Valley Center, 801 California Street, Mountain View, CA 94041 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

WO 2020/041466 A1

(54) Title: PLATELET COUNT-AGNOSTIC METHODS OF TREATING MYELOFIBROSIS

(57) Abstract: Reanalysis of the SIMPLIFY 1 and 2 trials data indicates MMB is effective in JAKi- naïve patients and in second line therapy to RUX, providing benefits of reducing enlarged spleens, improving myelofibrosis-related symptoms, and increasing transfusion independence in patient at risk for thrombocytopenia from the underlying disease and RUX therapy. Accordingly, methods of treating myeloproliferative neoplasms (MPN) such as myelofibrosis are described. The methods can include administering a therapeutically effective amount of momelotinib or a pharmaceutically acceptable salt thereof to a subject identified as having (i) myelofibrosis and (ii) a platelet count of less than 150 x 10^9/L. Also described are methods including administering to a subject with myelofibrosis a therapeutically effective stable dose of momelotinib or a pharmaceutically acceptable salt thereof, for a period of a plurality of weeks, where the subject is assessed as maintaining a platelet count above a predetermined threshold platelet count during the period.